Crescendo – Proprietary, robust, and highly efficient transgenic VH domain technology

The T cell enhancing company

Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer 3 February 2020

Publication in Cancer Research demonstrates Crescendo Biologics’ Humabody® VH therapeutics outperform conventional antibodies in vivo 15 January 2020

New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic 25 October 2019

Crescendo Biologics is focusing on novel T cell enhancing therapeutics in immuno-oncology.

Crescendo Biologics (Crescendo) is focused on transforming the lives of cancer patients through its pipeline of novel T cell enhancing therapies. The lead programme, CB307, is a first in class CD137 (4-1BB) x PSMA bispecific molecule. Behind the lead programme is a pipeline of other first or best in class CD137 (4-1BB) bispecifics for solid tumours.

T cell enhancing pipeline advantages:

Enhanced safety via conditional activation of tumour-specific T cells in the tumour micro-environment
Proliferation of tumour-specific T cells to enhance tumour cell killing
Survival of tumour-specific T cells for a more durable anti-cancer effect (‘memory’ responses)

Crescendo’s pipeline is underpinned by its proprietary Humabody® V_H platform. This platform is based on its transgenic mouse, from which are derived fully human V_H domains. These V_H domains can be used on their own or can be combined with other V_H domains to create multi-functional molecules with unique properties designed to overcome some of the limitations of traditional IgG-based molecules.